Gaithersburg’s Viela Bio soars on acquisition

Gaithersburg, Maryland-based Viela Bio, a company developing treatments for autoimmune and severe inflammatory diseases including COVID-19 lung damage, will be acquired by Dublin, Ireland-based Horizon Therapeutics in a deal worth nearly $3.1 billion.

News of the acquisition sent Viela Bio stock up more than 50% Monday. Viela Bio went public three years ago as a company spun off by Gaithersburg-based MedImmune.

Under terms of the acquisition, Horizon Therapeutics will pay $53 per share for Viela Bio’s outstanding stock in cash. The acquisition is expected to close by the end of the first quarter.

Horizon Therapeutics gains Viela Bio’s drug Uplizna, the only FDA-approved treatment for neuromyelitis optica spectrum disorder — a rare, severe autoimmune disease that attacks the optic nerve, spinal cord and brain stem.

Viela Bio also has experimental treatments in clinical trials COVID-19 related lung injury, as well as treatments for neuromuscular disease, lupus and other autoimmune and inflammatory diseases.

Viela Bio had $2.3 million in sales in its third quarter, all from Uplizna. It posted a quarterly loss of $37.6 million.

Like WTOP on Facebook and follow WTOP on Twitter and Instagram to engage in conversation about this article and others.

Get breaking news and daily headlines delivered to your email inbox by signing up here.

© 2021 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

Jeff Clabaugh

Jeff Clabaugh has spent 20 years covering the Washington region's economy and financial markets for WTOP as part of a partnership with the Washington Business Journal, and officially joined the WTOP newsroom staff in January 2016.

Federal News Network Logo

More from WTOP

Log in to your WTOP account for notifications and alerts customized for you.

Sign up